{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:29:45Z","timestamp":1790746185320,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T00:00:00Z","timestamp":1536796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005622","name":"Health Research","doi-asserted-by":"publisher","award":["916.151.94"],"award-info":[{"award-number":["916.151.94"]}],"id":[{"id":"10.13039\/100005622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jconrel.2018.09.004","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T08:28:54Z","timestamp":1536827334000},"page":"227-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis"],"prefix":"10.1016","volume":"288","author":[{"given":"Dhadhang Wahyu","family":"Kurniawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun Kumar","family":"Jajoriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1696-7753","authenticated-orcid":false,"given":"Josepmaria","family":"Argemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Storm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durga Prasad","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2470-5876","authenticated-orcid":false,"given":"Ruchi","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.09.004_bb0005","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jhep.2018.05.011","article-title":"Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies","volume":"69","author":"Pimpin","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0015","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: an update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0020","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.metabol.2015.12.009","article-title":"Nonalcoholic fatty future disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0025","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev-pharmtox-010617-052545","article-title":"Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies","volume":"58","author":"Wattacheril","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0035","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0040","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7629724","article-title":"Clinical advancements in the targeted therapies against liver fibrosis","volume":"2016","author":"Bansal","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/srep18272","article-title":"The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis","volume":"5","author":"Bansal","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/srep44545","article-title":"Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model","volume":"7","author":"Ozturk Akcora","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0055","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbadis.2017.12.001","article-title":"Inhibition of canonical WNT signaling pathway by beta-catenin\/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12","volume":"1864","author":"Akcora","year":"2018","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0060","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/acer.13096","article-title":"Therapeutic Benefits of Spleen Tyrosine Kinase Inhibitor Administration on Binge Drinking-Induced Alcoholic Liver Injury, Steatosis, and Inflammation in mice","volume":"40","author":"Bukong","year":"2016","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0065","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/hep.28680","article-title":"Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease","volume":"64","author":"Bukong","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0070","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/labinvest.2014.118","article-title":"Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis","volume":"94","author":"Shin","year":"2014","journal-title":"Lab. Investig."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29881","article-title":"Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis","author":"Qu","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0080","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0085","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/hep.26500","article-title":"Human ezrin-moesin-radixin proteins modulate hepatitis C virus infection","volume":"58","author":"Bukong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJMc1012187","article-title":"Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis","volume":"364","author":"Oton","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJMc1012187","article-title":"Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis","volume":"364","author":"Okamoto","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pupt.2007.06.002","article-title":"Syk inhibitors as treatment for allergic rhinitis","volume":"21","author":"Masuda","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0105","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1517\/14728222.9.5.901","article-title":"Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis","volume":"9","author":"Ulanova","year":"2005","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.biocel.2016.03.001","article-title":"Inhibition of spleen tyrosine kinase (syk) suppresses renal fibrosis through anti-inflammatory effects and down regulation of the MAPK-p38 pathway","volume":"74","author":"Chen","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0115","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1600-065X.2009.00837.x","article-title":"Autoinhibition and adapter function of Syk","volume":"232","author":"Kulathu","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0120","first-page":"364","article-title":"Therapeutic targeting of liver inflammation and fibrosis by nanomedicine","volume":"3","author":"Bartneck","year":"2014","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0125","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled dDrug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.colsurfb.2017.07.038","article-title":"Recent applications of PLGA based nanostructures in drug delivery","volume":"159","author":"Mir","year":"2017","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0135","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2010.01.036","article-title":"Endocytosis of nanomedicines","volume":"145","author":"Sahay","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0140","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/hep.26783","article-title":"Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice","volume":"59","author":"Baeck","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jconrel.2016.09.004","article-title":"Tumor stroma-containing 3D spheroid arrays: a tool to study nanoparticle penetration","volume":"244 (","author":"Priwitaningrum","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0150","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/hep.24395","article-title":"Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice","volume":"54","author":"Bansal","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0155","doi-asserted-by":"crossref","first-page":"46959","DOI":"10.18632\/oncotarget.10506","article-title":"Sex-specific metabolic interactions between liver and adipose tissue in MCD diet-induced non-alcoholic fatty liver disease","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0160","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cmet.2013.07.004","article-title":"DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery","volume":"18","author":"Ahrens","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0165","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0170","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1476-5381.2012.02097.x","article-title":"The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL","volume":"167","author":"Miller","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0175","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature07965","article-title":"Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence","volume":"459","author":"Gross","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.09.004_bb0180","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ctrv.2015.03.005","article-title":"Variability in bioavailability of small molecular tyrosine kinase inhibitors","volume":"41","author":"Herbrink","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0185","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpb.2006.06.009","article-title":"Effect of drug type on the degradation rate of PLGA matrices","volume":"64","author":"Siegel","year":"2006","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0190","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/eji.201041252","article-title":"The role of Syk\/CARD9 coupled C-type lectins in antifungal immunity","volume":"41","author":"Drummond","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0195","first-page":"1812","article-title":"AAL exacerbates pro-inflammatory response in macrophages by regulating Mincle\/Syk\/Card9 signaling along with the Nlrp3 inflammasome assembly","volume":"7","author":"Zhang","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.jconrel.2018.09.004_bb0200","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/hep.21614","article-title":"CCAAT\/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis","volume":"45","author":"Rahman","year":"2007","journal-title":"Hepatology"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918305248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918305248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T02:49:29Z","timestamp":1693882169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918305248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":40,"alternative-id":["S0168365918305248"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.09.004","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}